Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.7K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.7K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

668
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
668
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

247
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
247
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

275
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
275
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

344
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
344

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The association of sociodemographic differences with clinical management following a diagnosis of short cervix.

Pregnancy (Hoboken, N.J.)·2026
Same author

History of Treated Syphilis Before Pregnancy and Risk of Congenital Syphilis.

Obstetrics and gynecology·2026
Same author

Early Gestational Diabetes Mellitus: Screening and Management.

Clinical obstetrics and gynecology·2026
Same author

Prenatal exposure to SARS-CoV-2, early relational health, and child socio-emotional functioning in the first 6 months.

medRxiv : the preprint server for health sciences·2026
Same author

Pancreas Size and Fat Content Increase during Pregnancy and Correlate with Glycemic Control.

American journal of perinatology·2026
Same author

Labour and delivery characteristics, maternal birth satisfaction and early relational health among COVID-19 pandemic-born children.

Journal of reproductive and infant psychology·2026

Related Experiment Video

Updated: Sep 1, 2025

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring
06:11

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring

Published on: May 17, 2024

751

Early Gestational Diabetes Screening Based on ACOG Guidelines.

Macie L Champion1, Victoria C Jauk1, Joseph R Biggio2

  • 1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, The University of Alabama at Birmingham, Birmingham, Alabama.

American Journal of Perinatology
|August 16, 2022
PubMed
Summary
This summary is machine-generated.

Early gestational diabetes screening in obese patients does not improve perinatal outcomes, regardless of risk factors. Increased risk factors correlate with higher GDM incidence and adverse outcomes, suggesting current screening guidelines may need re-evaluation.

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.9K
Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

15.6K

Related Experiment Videos

Last Updated: Sep 1, 2025

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring
06:11

Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring

Published on: May 17, 2024

751
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.9K
Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

15.6K

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Endocrinology

Background:

  • Current guidelines recommend early gestational diabetes mellitus (GDM) screening for overweight patients with risk factors.
  • A prior study indicated early GDM screening in obese patients (BMI ≥30 kg/m²) does not improve perinatal outcomes.
  • This study investigates GDM screening effectiveness based on the number of additional risk factors in obese patients.

Purpose of the Study:

  • To evaluate the impact of early versus routine GDM screening on perinatal outcomes stratified by the number of additional risk factors in obese patients.
  • To determine if the number of risk factors modifies the effect of early GDM screening on adverse perinatal outcomes.
  • To analyze the relationship between the number of risk factors and GDM incidence and perinatal outcomes.

Main Methods:

  • Secondary analysis of a multicenter randomized controlled trial comparing early (14-20 weeks) with routine (24-28 weeks) GDM screening in obese patients.
  • Patients were stratified by the number of additional GDM risk factors (0, 1, 2, ≥3).
  • The primary outcome was a composite of adverse perinatal events; GDM diagnosis and outcomes were analyzed based on screening timing and risk factor count.

Main Results:

  • The study included 913 obese patients, with risk factor distribution: 5% (0), 52% (1), 33% (2), and 10% (≥3).
  • No significant interaction was found between early/routine screening and the number of risk factors for the primary outcome (p=0.37) or GDM diagnosis (p=0.28).
  • Both GDM incidence and adverse perinatal outcomes increased significantly with a higher number of risk factors (p<0.001).

Conclusions:

  • Early GDM screening does not confer benefits for perinatal outcomes in obese patients, even those with additional risk factors.
  • The number of risk factors is a significant predictor of both GDM development and adverse perinatal outcomes.
  • Findings suggest that focusing on risk factor management rather than solely on early screening timing may be more beneficial for this population.